12-8077
Anti-Human IL 12/23 (Briakinumab) - Fc Muted™ Biotin
Abeomics
DESCRIPTION
Expression Host : HEK-293
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.
Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23alpha to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
DETAILS
- App Id: ELISA
- Antigen: IL-12/IL-23 p40
- Isotype: Human IgG1lambda
- Clone Name: ABT-874
- Host Animal: Human
- Clonality Id: Monoclonal
- Reactivity Id: Human
- Product Content: Concentration : 0.5 mg/mlThis Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
- Alternative Name: IL-12p40; Interleukin 12; Interleukin 23; IL12; IL23; IL-12; IL-23
- Application Note: The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.ELISA
- Storage Condition: This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
- Immunogen Information: This antibody was produced by phage display technology.